Hybio Pharmaceutical announced that the company has again received a procurement demand order from the American partner Hikma. Hikma intends to purchase Liraglutide Injection (generic drug) from the company for an amount of 10.5624 million US dollars (equivalent to approximately 0.077 billion yuan, including tax). As of the date of this announcement, the total contract amount signed by the company and Hikma is approximately 0.338 billion yuan.